^
Association details:
| Biomarker: | B2M elevation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | Proteasome inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
TRANSLOCATION (14;16) POSITIVE MULTIPLE MYELOMA PATIENTS: CLINICAL FEATURES AND SURVIVAL OUTCOMES OF A HIGH-RISK POPULATION.
Published date:
05/17/2018
Excerpt:
Induction therapy consisted of an immunomodulatory drug, a proteasome inhibitor or a combination of both....In the multivariate analysis, baseline hypercalcemia and beta-2-microglobulin >ULN were associated with significantly shorter PFS (HR: 2.3, p=0.02; HR: 2.7, p=0.001, respectively) and OS (HR: 5.4, p<0.001; HR: 1.9, p=0.02, respectively)...
